A. Asberg, A. Humar, A. G. Jardine, H. Rollag, M. D. Pescovitz, H. Mouas, A. Bignamini, H. T?z, I. Dittmer, M. Montejo and A. Hartmann, “Long-Term Outcomes of CMV Disease Treatment with Valganciclovir versus IV Ganciclovir in Solid Organ Transplant Recipients,” American Journal of Transplantation, Vol. 9, No. 5, 2009, pp. 1205-1213. doi:10.1111/j.1600-6143.2009.02617.x

has been cited by the following article:

• TITLE: A Case of Cytomegalovirus-Induced Arthritis after Lymphocyte-Depleting Therapy for Kidney Allograft Rejection

  AUTHORS: Richard Fuquay, James Eric Cooper

  KEYWORDS: Cytomegalovirus (Mesh); Arthritis (Mesh); Kidney Transplantation (Mesh); Immunosuppression (Mesh); Chemoprevention (Mesh); Valganciclovir (Mesh)

  JOURNAL NAME: Open Journal of Nephrology, Vol.2 No.1, March 28, 2012

  ABSTRACT: Cytomegalovirus viremia and tissue-invasive disease are common after kidney transplantation. Chemoprophylaxis has made substantial improvement in this clinical problem. Here we report a 29-year-old woman who had kidney allograft rejection and received lymphocyte-depleting therapy. She presented with a new oligo-arthritis that led to 2 successive arthrocenteses. The etiology of the inflammation could not be determined initially. On the second arthrocentesis, a synovial fluid cytomegalovirus polymerase chain reaction test was positive. The patient responded to treatment with valganciclovir, had negative follow-up serum cytomegalovirus polymerase chain reaction tests, and experienced resolution of her joint inflammation. We review briefly the data for cytomegalovirus chemoprophylaxis, preemptive screening, and treatment recommendations.